- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs | Clinical
Phase 3 Study of Imtelstat Versus BAT Explores Survival Improvement in Myelofibrosis
April 15, 2021
A phase 3 study with the goal of demonstrating overall survival benefit with imetelstat versus best available therapy in patients with refractory myelofibrosis has dosed the first patient with the experimental agent.
Parsaclisib Added to Ruxolitinib Improves Spleen Size and Symptom Burden in Myelofibrosis
April 11, 2021
The addition of parsaclisib to ruxolitinib led to improvement in spleen volume reduction and symptom burden in patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone, according to results from a phase 2 study.
FDA Approval Sought for Pacritinib to Treat Patients with Myelofibrosis and Severe Thrombocytopenia
April 01, 2021
A rolling submission of a New Drug Application has been completed for pacritinib which is seeking FDA approval as a treatment for patients with myelofibrosis who have severe thrombocytopenia.
Givinostat Shows Promise for Long-Term Use in Patients With Polycythemia Vera
March 31, 2021
In patients with polycythemia vera, long-term use of the histone deacetylase inhibitor givinostat may be warranted after the agent demonstrated tolerable safety and good efficacy over a 4-year period in an ongoing, multicenter, open-label, single-arm study of patients with a chronic myeloproliferative neoplasm who are positive for a JAK2 V617F mutation.
Ruxolitinib/Navitoclax Shows Efficacy in Relapsed/Refractory Myelofibrosis
March 20, 2021
Naveen Pemmaraju, MD, discusses the results of combining ruxolitinib and navitoclax in different high-risk populations of relapsed/refractory myelofibrosis.
Thrombosis Risk in Patients With MPNs and COVID-19 Highest for Patients With Essential Thrombocythemia
March 19, 2021
Major thrombosis is a significant danger for patients with MPN who become infected with COVID-19, and antithrombotic prophylaxis does not appear to eliminate the risk.
FDA Issues CRL for Ropeginterferon alfa-2b-njft BLA in PV
March 15, 2021
The FDA has issued a complete response letter to PharmaEssentia Corporation for the company’s biologics license application for ropeginterferon alfa-2b-njft as a potential treatment for patients with polycythemia vera.
BET Inhibitor CPI-0610 Shows Potential as Treatment in Myelofibrosis
February 24, 2021
Lucia Masarova, MD, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST trial in patients with myelofibrosis.
Peri-Transplant Administration of Ruxolitinib Safe and Feasible in Myelofibrosis
February 17, 2021
Ruxolitinib is one of only 2 treatments for MF that significantly improved the survival of patients. Still oncologists see opportunity to prolong survival in these patients even more.
Safety Findings Support Use of Peri-Transplant Ruxolitinib in Myelofibrosis
February 10, 2021
Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.